MetLife (MET) director Kennard granted 587 deferred shares as board compensation

Rhea-AI Filing Summary

Kennard William E reported acquisition or exercise transactions in this Form 4 filing.

MetLife Inc. director William E. Kennard received a grant of 587 shares of common stock as non-management director compensation. The award was valued at $87.40 per share and increased his direct holdings to 47,410 shares. He elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. The filing also shows 10 shares of common stock held indirectly through the MetLife Policyholder Trust.

Insights

Corporate governance analyst

Routine stock-based fee payment to MetLife director, not a market trade.

Non-management director William E. Kennard received 587 MetLife common shares as part of standard director retainer fees, at $87.40 per share. This is compensation delivered in equity, not an open-market purchase or sale.

The director elected to defer these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, indicating long-term alignment but providing no trading signal. He now holds 47,410 shares directly, plus 10 shares indirectly via the MetLife Policyholder Trust.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kennard William E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	587	$87.40	$51K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 47,410 shares (Direct, null); Common Stock — 10 shares (Indirect, By the MetLife Policyholder Trust)

Footnotes (1)

1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Key Figures

Director stock grant: 587 shares Grant valuation price: $87.40 per share Direct holdings after grant: 47,410 shares +2 more

5 metrics

Director stock grant 587 shares Common stock grant as non-management director compensation

Grant valuation price $87.40 per share Valuation applied to the 587-share director grant

Direct holdings after grant 47,410 shares Total MetLife common shares held directly after transaction

Indirect trust holdings 10 shares Shares held in MetLife Policyholder Trust

Transaction code A (grant/award acquisition) Indicates stock was awarded, not bought on the market

Key Terms

MetLife Deferred Compensation Plan for Non-Management Directors, non-management director retainer fees, MetLife Policyholder Trust, grant, award, or other acquisition

4 terms

MetLife Deferred Compensation Plan for Non-Management Directors financial

"The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors."

non-management director retainer fees financial

"non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock."

MetLife Policyholder Trust financial

"Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders"

grant, award, or other acquisition regulatory

"transaction_code_description": "Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennard William E

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		A(1)		587	A	$87.4	47,410	D
Common Stock								10	I	By the MetLife Policyholder Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

2. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MetLife (MET) director William E. Kennard report in this Form 4?

He reported a grant of 587 shares of MetLife common stock as part of his non-management director retainer fees, valued at $87.40 per share, increasing his direct holdings to 47,410 shares after the transaction.

Was the MetLife (MET) Form 4 transaction a market buy or sell?

No, the Form 4 shows a grant of 587 shares as compensation, coded as a grant or award. It is not an open-market purchase or sale, but equity paid in lieu of cash retainer fees to the non-management director.

How many MetLife (MET) shares does William E. Kennard hold after this filing?

After the reported grant, he holds 47,410 MetLife common shares directly. The filing also shows 10 additional shares held indirectly through the MetLife Policyholder Trust, which holds stock allocated to eligible policyholders.

What is the price associated with the MetLife (MET) director share grant?

The 587-share grant is reported at a price of $87.40 per MetLife common share. This figure reflects the valuation used for the director’s equity-based retainer compensation under MetLife’s non-management director arrangements.

What is the MetLife Deferred Compensation Plan for Non-Management Directors?

It is a plan allowing non-management directors to defer receipt of stock-based retainer fees. In this filing, William E. Kennard elected to defer the 587-share grant under this plan rather than taking immediate delivery of the shares.

What are the MetLife Policyholder Trust shares mentioned in this Form 4?

The Form 4 notes 10 shares of common stock held in the MetLife Policyholder Trust. This trust holds shares allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned MetLife subsidiary, and is reported as indirect ownership.